Canha Dulce, McMahon Virginia, Schmitz Susanne, De Beaufort Carine, Alzaid Fawaz, Reznik Yves, Riveline Jean-Pierre, Fagherazzi Guy, Aguayo Gloria A
Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.
Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Diabet Med. 2025 Apr;42(4):e15503. doi: 10.1111/dme.15503. Epub 2024 Dec 26.
Diabetes distress (DD) is prevalent among people with diabetes. While automated insulin delivery systems (AIDs) improve glycaemic control, their impact on DD is unclear. We aimed to investigate the effect of AIDs on DD in people with diabetes and their caregivers.
We focused on people with diabetes using AIDs versus other insulin delivery systems, with DD as the outcome. We included randomised controlled trials (RCTs), before-after studies (BAS) and observational studies until 4 April 2024. After screening, 40 studies were included in the systematic review, comprising 5426 participants (3210 adults, 1131 paediatric and 1085 caregivers). Twenty-seven studies were selected for the meta-analysis (focusing solely on type 1 diabetes). We used random effects models by population and study design. We also conducted a subgroup analysis by age group (children vs. teenagers).
In adults, eight BAS and five RCTs indicated a significant small DD reduction post-AID initiation (standardised mean difference [95% confidence intervals] -0.32 [95% CI: -0.40, -0.24] and [-0.19 (-0.27, -0.11)]). No significant changes were observed in the paediatric population. In caregivers, eleven BAS and five RCTs indicated a significant moderate DD reduction (-0.48 [95% CI: -0.78, -0.18] and (-0.22 [-0.38, -0.06])). Subgroup analysis revealed an increased benefit in parents of children compared to parents of teenagers.
This work suggests that AIDs is associated with a DD reduction in adults and caregivers but not in children/teenagers with type 1 diabetes. More longitudinal studies and better systematic DD assessments are needed.
糖尿病困扰(DD)在糖尿病患者中普遍存在。虽然自动胰岛素输送系统(AIDs)可改善血糖控制,但其对糖尿病困扰的影响尚不清楚。我们旨在研究AIDs对糖尿病患者及其照护者的糖尿病困扰的影响。
我们聚焦于使用AIDs的糖尿病患者与使用其他胰岛素输送系统的患者,以糖尿病困扰为观察结果。我们纳入了截至2024年4月4日的随机对照试验(RCTs)、前后对照研究(BAS)和观察性研究。筛选后,40项研究被纳入系统评价,共5426名参与者(3210名成年人、1131名儿童和1085名照护者)。27项研究被选入荟萃分析(仅关注1型糖尿病)。我们根据人群和研究设计使用随机效应模型。我们还按年龄组(儿童与青少年)进行了亚组分析。
在成年人中,八项前后对照研究和五项随机对照试验表明,开始使用AIDs后糖尿病困扰有显著小幅降低(标准化均数差[95%置信区间]-0.32[95%CI:-0.40,-0.24]和[-0.19(-0.27,-0.11)])。儿科人群中未观察到显著变化。在照护者中,十一项前后对照研究和五项随机对照试验表明糖尿病困扰有显著中度降低(-0.48[95%CI:-0.78,-0.18]和(-0.22[-0.38,-0.06]))。亚组分析显示,与青少年的父母相比,儿童的父母受益更大。
这项研究表明,AIDs与成年人及照护者的糖尿病困扰降低有关,但与1型糖尿病儿童/青少年的糖尿病困扰降低无关。需要更多的纵向研究和更好的系统性糖尿病困扰评估。